Production of Humanized Antibody against Human High-affinity IgE Receptor in a Serum-free Culture of CHO Cells, and Purification of the Fab Fragments

We describe the preparation of Fab fragments of a humanized anti-human high-affinity IgE receptor (FcεRIα) antibody potentially useful for treatment of IgE-mediated allergic diseases. IgE-binding capacities of sixteen combinations of light and heavy chains of four recombinant anti-FcεRIα antibodies,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioscience, biotechnology, and biochemistry biotechnology, and biochemistry, 2001-05, Vol.65 (5), p.1082-1089
Hauptverfasser: TAKAI, Toshiro, TAKAHASHI, Kyoko, AKAGAWA-CHIHARA, Midori, FUKADA, Minako, YUUKI, Toshihumi, SHIBUYA, Ichiro, OKUMURA, Ko, RA, Chisei, YOKOTA, Toyokazu, OKUMURA, Yasushi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We describe the preparation of Fab fragments of a humanized anti-human high-affinity IgE receptor (FcεRIα) antibody potentially useful for treatment of IgE-mediated allergic diseases. IgE-binding capacities of sixteen combinations of light and heavy chains of four recombinant anti-FcεRIα antibodies, chimeric CRA2, humanized CRA2, chimeric CRA4, and humanized CRA4, were compared. A combination in which both chains were of humanized CRA2 had the highest activity. Stable transfectant clones of four kinds of host cells expressing recombinant antibodies were established. CHO-K1 cells were the most productive. Serum-free media suitable for culture of the stable CHO-transfectant clones were screened. The concentration of the humanized CRA2, which the most productive clone secreted into the chosen serum-free medium, was approximately 100 μg/ml. A procedure for the purification of the antibody, papain-digestion, and purification of Fab fragments was established. The highly purified humanized Fab fragments are suitable for use to examine their in vivo activity and immunogenicity in primates.
ISSN:0916-8451
1347-6947
DOI:10.1271/bbb.65.1082